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PseudovirusNeutralization properties of human immunodeﬁciency virus (HIV-1) are often deﬁned using pseudoviruses
grown in transformed cells, which are not biologically relevant HIV-1 producer cells. Little information exists
on how these viruses compare to viruses produced in primary lymphocytes, particularly for globally relevant
HIV-1 strains. Therefore, replication-competent chimeras encoding envelope variants from the dominant
HIV-1 subtypes (A, C, and D) obtained early after infection were generated and the neutralization properties
explored. Pseudoviruses generated in 293T cells were the most sensitive to antibody neutralization. Replicat-
ing viruses generated in primary lymphocytes were most resistant to neutralization by plasma antibodies and
most monoclonal antibodies (b12, 4E10, 2F5, VRC01). These differences were not associated with differences
in envelope content. Surprisingly, the virus source did not impact neutralization sensitivity of most viruses to
PG9. These ﬁndings suggest that producer cell type has a major effect on neutralization sensitivity, but in an
antibody dependent manner.
© 2012 Elsevier Inc. All rights reserved.Introduction
A strong humoral immune response to human immunodeﬁciency
virus type 1 (HIV-1) is considered integral to any effective vaccine re-
sponse (Burton et al., 2004; Mascola and Monteﬁori, 2010). Thus, in
vitro assays that measure HIV-1 speciﬁc neutralizing antibodies that
can be used in high-throughput screening are essential. The most
commonly used assay to measure HIV-1-speciﬁc neutralization em-
ploys a pseudovirus capable of a single round of infection and an indi-
cator cell line that expresses high levels of the HIV-1 receptors [TZM-
bl also named JC53BL (Li et al., 2005; Platt et al., 1998; Wei et al.,
2003)]. However, at present, there is little evidence for a correlation
between neutralizing antibody titers measured by the commonly
used in vitro neutralization assays and protection from HIV-1 infec-
tion in humans. Thus, there is substantial interest in other assays to
measure HIV-1 speciﬁc antibody activity, including other neutraliza-
tion assays, such as those using peripheral blood mononuclear cells
(PBMCs) (Brown et al., 2008) and antibody-dependent cellular viral
inhibition (ADCVI) assays, which capture other non-neutralizing anti-
body activities [reviewed in (Chung et al., 2008; Forthal and Moog,logy, Fred Hutchinson Cancer
WA 98109-1024, USA.
eth Israel Deaconess Medical
.
rights reserved.2009)]. Such assays require the use of replication-competent viruses,
of which relatively few exist [only 30 full-length infectious viral iso-
lates are available in the NIH AIDS Research and Reference Reagent
Program (aidsreagents.org)]. Since the target of neutralizing anti-
bodies is the HIV-1 envelope protein, one alternative approach to
generate genetically diverse replication-competent viruses for these
assays is to create chimeric viruses using a common full-length HIV-
1 provirus and introducing diverse heterologous envelope sequences
into this provirus.
A major outstanding question with regard to the use of these
replication-competent chimeras is how similar is a virus generated
from a chimeric provirus compared to a pseudovirus, generated by
co-transfection, that contains identical genes (hereafter “isogenic”).
Two studies have examined the effect on envelope expression context
(either as a pseudovirus versus full-length virus) and found that this
did not affect neutralization phenotype (Louder et al., 2005; Provine
et al., 2009). The study by Louder and colleagues using three CXCR4
or dual-tropic subtype B envelope variants from chronic infection,
reported that replication-competent chimeras and isogenic pseudo-
viruses exhibited equivalent neutralization sensitivity when tested
against a panel of broadly neutralizing monoclonal antibodies
(MAbs) (Louder et al., 2005). Similar results were observed in a
study of two CCR5-using subtype A variants from chronic infection
using MAbs and entry inhibitors (Provine et al., 2009).
Another relevant issue with the use of pseudoviruses for the study
of neutralization sensitivity is that they are generated in transformed
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used for single-cycle assays such as the TZM-bl assay are typically
generated in human embryonic kidney (HEK) 293T cells, because it
is possible to produce large amounts of virus by transient transfection
in these cells (Graham et al., 1977). While a number of studies have
examined the role of producer cell type on neutralization phenotype
(Sawyer et al., 1994; Zhang et al., 1997), only two directly compared
293T cells and primary cells such as PBMCs as the producer cells
(Louder et al., 2005; Mann et al., 2009). The study by Louder et al.,
demonstrated that for three CXCR4-using subtype B variants, genera-
tion of replication-competent chimeras in PBMCs signiﬁcantly de-
creased neutralization sensitivity compared to 293T-derived virus
from the same chimera (Louder et al., 2005). A separate study using
clade B viral isolates from both acute and chronic infection also
found that growth of virus in PBMC decreased neutralization sensitiv-
ity to the MAb 2G12, which recognizes a collection of glycan residues
on the viral envelope (Mann et al., 2009; Trkola et al., 1996). Howev-
er, this study used primary isolates derived by short-term co-culture
of patient PBMCs rather than cloned viruses, and therefore the pseu-
doviruses and replication-competent viruses were not identical. Fur-
thermore, most non-clade B viruses lack the 2G12 epitope so these
ﬁndings cannot be recapitulated using most pandemic relevant provi-
ral clones (Blish et al., 2009). Nonetheless, these studies collectively
suggest that the source of virus may have a signiﬁcant impact on
the assessment of neutralization sensitivity.
To date there are no data examining neutralization differences of
isogenic replication-competent HIV-1 and corresponding pseudo-
virus encoding envelope variants that represented early-stage vari-
ants of the major circulating subtypes, which are of particular
interest for assessing vaccine responses and their efﬁcacy. Therefore,
we have characterized the role of envelope expression context and
producer cell type for nine novel replication-competent chimeric
HIV-1 isolates from the dominant circulating HIV-1 subtypes in Africa,
where most new HIV-1 infections are occurring.
Results
Infectivity and replication properties of chimeric viruses
Nine full-length chimeric proviruses (Table 1) were generated
using a full-length proviral clone, Q23-17, that was obtained from a
subtype-A infected Kenya woman early in infection (Poss and
Overbaugh, 1999). The original provirus was modiﬁed to allow intro-
duction of unique restriction sites (SmaI and XhoI) ﬂanking the enve-
lope gene to generate Q23XhoΔXho, and envelope sequences wereTable 1
Characterization of envelope variants.
Original envelope variant namea Name used here Clade Length of infectionb
Q23-17 env Q23-17 env A 142 dpi
Q168.b23 Q168.b23 A 23 dpi
Q461.e2 Q461.e2 A 28 dpi
MG505.W0M.ENV.C2 MG505.C2 A Chronic
MS208.W6B.ENV.A3 MS208.A3 A Chronic
BJ613.W6M.ENV.E1 BJ613.E1 A Week 6
BS208.W6M.ENV.B1 BS208.B1 A Week 6
QB099.391M.ENV.B1 QB099.B1 C 391 dpi
QC406.70M.ENV.F3 QC406.F3 C 70 dpi
BJ412.W6M.ENV.S3 BJ412.S3 C Week 6
QA013.70I.ENV.M12 QA013.M12 D 70 dpi
QD435.100M.ENV.A4 QD435.A4 D 100 dpi
a The original nomenclature for the published envelope, and used for the sequence desig
ignation is truncated as indicated, and this abbreviated version is used throughout the text
b For adults, this estimate is based on published data and methods for estimating time of
time post infection is the ﬁrst time point where the infant was HIV-1 positive after birth as
c Blood=isolated directly from PBMCs from the individual, either adult or infant as denot
term culture in PBMCs from an adult individual.
d The Tier designation was estimated based on comparison with viruses that have been deintroduced as described (Provine et al., 2009). A schematic of the con-
struct used to generate these chimeras is shown in Fig. 1A. The enve-
lope variants chosen included subtype A, C, and D variants and thus
represent the most common circulating strains of HIV-1 in Africa.
Eight of nine of these envelopes clones were derived directly from
the cells of infected individuals without culturing and all but one is
from within 6 months of infection (range 23–142 days). Since it is
not possible to identify individuals at the precise time they acquired
HIV and isolate the precise viral sequence that led to their infection,
the study of these variants from very early in infection provides a use-
ful surrogate for viruses that successfully established a new infection
(Table 1). Two previously generated chimeras from chronically
infected transmitting mothers were also included, MG505.C2 chimera
and MS208.A3 chimera (Provine et al., 2009), as well as the parental
virus, Q23XhoΔXho, listed as Q23-17 env as this is the envelope
gene expressed by the virus (Table 1). In all cases, the replication-
competent provirus was compared to pseudovirus generated with
the corresponding envelope sequences and a Q23-17 provirus deleted
in env (Q23Δenv) (Poss and Overbaugh, 1999).
The viral titers of the isogenic pseudoviruses and replication-
competent chimeras generated by transfection of HEK 293T cells
were generally high, ranging from 2×104 to as high as 6×107 infec-
tious particles per ml (Fig. 1B). However, there were virus speciﬁc dif-
ferences in the relative titer of the pseudovirus compared to the
isogenic replication-competent chimera. On one extreme, the
replication-competent chimeras of BJ412.S3 and BJ613.E1 as well as
the parental Q23-17 env produced approximately 10-times as many
infectious particles as the pseudovirus system, despite transfection
of equal amounts of DNA (Fig. 1B). In contrast, the pseudovirus sys-
tems of QA013.M12, Q168.B23, and Q461.e2 all produced at least
10-times as many infectious particles as the isogenic chimera system
(Fig. 1B).
To test whether the modiﬁcation of the Q23-17 provirus, by muta-
tion of a XhoI site to facilitate chimera creation, had any impact on
replication properties, we compared replication of the parental Q23-
17 virus and the modiﬁed Q23XhoΔXho, which differs at one amino
acid in Nef. There was no signiﬁcant difference in titer between
virus generated from the Q23-17 proviral HIV-1 clone and the
Q23XhoΔXho clone (Fig. 1C; p=0.4, Mann–Whitney U-test) suggest-
ing that the modiﬁcation of the cloning sites in Q23-17 to generate a
unique XhoI site did not alter the replication properties. Additionally,
Q23XhoΔXho was compared to full-length Q23-17 in all subsequent
experiments and no notable difference between the two constructs
was found (data not shown). The Q23-17 env chimeric virus
(Q23XhoΔXho) produced the highest titer of virus (6.4×107Virus sourcec Tierd Reference
Blood, adult 1b Long et al. (2002) and Poss and Overbaugh (1999)
Blood, adult 1b Long et al. (2002)
Blood, adult 2 Long et al. (2002)
Blood, adult 2 Wu et al. (2006)
Breast milk 2 Rainwater et al. (2007)
Blood, infant 2 Wu et al. (2006)
Blood, infant 2 Wu et al. (2006)
Blood, adult 2 Blish et al. (2009)
Blood, adult 2 Blish et al. (2009)
Blood, infant 2 Wu et al. (2006)
Primary isolate, adult 2 Blish et al. (2009)
blood, adult 2 Blish et al. (2009)
nation in Genbank (http://www.ncbi.nlm.nih.gov/genbank/). The longer envelope des-
and ﬁgures.
infection as described (Lavreys et al., 2004). For infants (BJ412, BJ613, and BS208), the
described (Wu et al., 2006).
ed; Breast milk=isolated from breast milk cells; Primary isolate=isolated after short-
scribed in prior studies (Seaman et al., 2010), as deﬁned in the Materials and methods.
Fig. 1. Generation and characterization of chimeric proviruses encoding diverse enve-
lope variants. (A) Schematic of the chimeric proviruses derived from Q23XhoΔXho. Re-
striction sites used to introduce envelope sequences, SmaI and XhoI, are shown. The
numbering refers to the 5′ (SmaI) and 3′ (XhoI) most extents of the restriction sites
based on the Q23-17 genome (Genbank ID: AF004885). The portions of the chimeras
that are derived from Q23XhoΔXho (LTRs, gag, pol, vif, and vpr) are shown in white
boxes, those derived from the insert sequences (vpu, env, and rev) are shown in
hatched boxes. The tat and nef genes are chimeras of the two viral strains. (B) Infec-
tious titer of replication-competent chimeras compared to isogenic pseudoviruses gen-
erated in 293T cells. IP/ml refers to infectious particles per ml (IP/ml) determined using
TZM-bl reporter cells. Black bars indicate the IP/ml for the pseudovirus while white
bars indicate the IP/ml of the virus derived from the chimeric provirus; the envelope
of each pair tested is shown at the bottom of the graph. The data represent the results
of at least two separate experiments (each performed in duplicate); mean and SEM are
shown. Dashed line denotes minimum IP/ml needed to perform the neutralization
assay. (C) Infectious titer of the Q23XhoΔXho compared to the parental virus, Q23-
17, which is the wild-type Q23 viral provirus prior to manipulation of the XhoI site
for cloning (Provine et al., 2009). (D) Infection of PBMCs with the chimeric viruses gen-
erated in 293T cells. The envelope insert of each virus is listed. PBMC were infected
with 293T-derived replication-competent chimera at an MOI of 0.01. The graph
shows the IP/ml (infectious particles per ml determined in TZM-bl reporter cells) in
cell-culture supernatant versus days post-infection. The symbol corresponding to the
viruses tested is shown to the right of the graph. Representative data from one of
two PBMC infections are shown. Dashed line denotes minimum IP/ml needed to per-
form the neutralization assay.
Fig. 2. Comparison of virus source on neutralization sensitivity to an HIV-1 positive
plasma pool. The source of the virus is shown on the x-axis: 293T-PV denotes pseudo-
virus obtained by transfecting 293T cells; 293T-Chm denotes virus obtained by trans-
fecting 293T cells with a chimeric provirus; PBMC-Chm denotes virus obtained by
infecting PBMCs with 293T-derived chimeric virus. The envelope of the various virus
types is indicated to the right with the corresponding symbol. In the case of the chime-
ric viruses, the indicated designated envelope corresponds to the chimeric provirus in
Fig. 1D. The IC50 (50% inhibitory concentration) is shown on the y-axis, and each sym-
bol represents the mean IC50 of that virus calculated from a minimum of three exper-
iments, each performed in triplicate. If a sample failed to reach 50% neutralization or
was neutralized greater than 50% at the greatest dilution tested, the IC50 was set as
the highest or lowest dilution of plasma tested, respectively. Dashed line denotes high-
est concentration of plasma tested. Solid line represents the median IC50 of each group.
The P-value, shown above, was calculated by Wilcoxon signed-rank test. The HIV-1
positive plasma pool was obtained by pooling plasma from 31 HIV-1 positive individ-
uals from Kenya.
27N.M. Provine et al. / Virology 427 (2012) 25–33infectious particles per ml), but there were a number of chimeras that
produced similar levels of infectious virus (Fig. 1B). These results
demonstrate that introduction of a heterologous envelope gene does
not generally impair virus replication.
The chimeras were also assessed for their ability to establish
spreading infection in human PBMCs in culture. Nine of the 12
replication-competent chimeras replicated to high titer in PMBCs,
with a titer of >105 infectious particles by day nine (Fig. 1D). In
most cases, viral titer increased until day 12, but had diminished by
day 15, presumably due to infected cell death. The titers of two virus-
es, QC406.F3 chimera and Q168.B23 chimera, dropped below detec-
tion by day 6 (data not shown). A third virus, MG505.C2 chimera
established low level persistent infection over the 15 days in culture(Fig. 1D). However, the titer never reached the 2×104 IP/ml needed
to perform subsequent experiments (dashed horizontal line,
Fig. 1D). These three viruses were therefore excluded from subse-
quent studies utilizing PBMC-derived viruses. Several viruses repli-
cated to equivalent levels as Q23-17 env (Fig. 1D), again suggesting
that introduction of a heterologous envelope does not necessarily
negatively affect virus replication capacity.Both envelope expression context and producer cell type affect sensitivity
of HIV-1 to plasma antibody neutralization
Pooled plasma was used to examine the affect of the virus source
on neutralization sensitivity against HIV-1 speciﬁc antibodies in plas-
ma from HIV-1 infected individuals. The plasma was from HIV-1-
infected Kenyans, and presumably includes individuals infected
with subtypes A, C, and D, which are the common subtypes in this re-
gion (Neilson et al., 1999). This plasma pool was tested against the
pseudoviruses, isogenic 293T-derived chimeras, and the PMBC-
derived chimeras. The chimeras generated in 293T cells exhibited a
1.8-fold decrease in sensitivity to neutralization compared to the
pseudoviruses when tested against the HIV-1 positive plasma pool
(Fig. 2; Supplemental Table 1). The difference in IC50s (reciprocal di-
lution of plasma required to neutralize 50% of the virus) between the
two groups was statistically signiﬁcant (p=0.05). For ten of the vi-
ruses, the differences in IC50 values between pseudovirus and chime-
ra were approximately two-fold or less. However, two isolates were
dramatically more resistant when generated as 293T-derived chi-
meras. 293T-derived Q461.e2 chimera was approximately four-fold
more resistant to neutralization than the matched pseudovirus, and
293T-derived QA013.M12 chimera was approximately 16-fold more
resistant. These results suggest that virus generated from full-length
replication-competent virus is generally more resistant to neutraliza-
tion that an isogenic pseudovirus, although the magnitude of the dif-
ference is small. However, isolated speciﬁc differences can be several-
fold greater than the median difference observed between the groups.
Two other groups had noted decreased neutralization sensitivity
for subtype B HIV-1 grown in PBMCs compared to 293T cells
(Louder et al., 2005; Mann et al., 2009). To determine if growth of
Fig. 3. Effect of virus source on neutralization phenotype to the ﬁrst generation broadly
neutralizing monoclonal antibodies. The layout for this ﬁgure is as described in the leg-
end to Fig. 2, with results for different monoclonal antibodies shown for each panel.
(A) Viruses tested against the CD4 binding site directed MAb IgG1 b12 (Burton et al.,
1994). (B) Viruses tested against the gp41 directed MAb 4E10 (Zwick et al., 2001).
(C) Viruses tested against the gp41 directed MAb 2F5 (Muster et al., 1993). Each sym-
bol represents the mean IC50 of the virus indicated by the envelope it contains to the
right, calculated from a minimum of two experiments, performed in triplicate.
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zation susceptibility as the subtype B variants, nine replication-
competent chimeras that were capable of growth in PBMCs (all but
MG505.C2 chimera, QC406.F3 chimera, and Q168.B23 chimera)
were generated in 293T cells and in PBMCs and compared. When
the effect of producer cell type was examined, a 2.7-fold reduction
in median neutralization sensitivity of the PBMC-derived chimera
was observed when compared to the 293T-derived chimera (Fig. 2;
p=0.03). Not all viruses were more resistant to neutralization
when grown in PBMCs compared to 293T cells; three chimeras were
slightly more sensitive to neutralization (BJ412.S3, QA013.M12, and
Q461.e2). Overall the magnitude of differences between 293T-
derived and PBMC-derived isolates was not variable from one isolate
to the next. Only MS208.A3 exhibited an IC50 that was greater than
four-fold different between the 293T-derived and PBMC-derived chi-
meras. Replication-competent virus grown in PBMC was ﬁve-fold
more resistant to neutralization than pseudovirus generated in 293T
cells. In sum, these data demonstrate that producer cell type has a
major effect on neutralization sensitivity of isolates to plasma from
HIV-1-infected individuals.
Producer cell type, not envelope expression context, affects sensitivity to
neutralizing MAbs of moderate potency
The neutralization sensitivities of the twelve isogenic pairs of
pseudoviruses and replication-competent chimeras were compared
using three moderately potent HIV-1 speciﬁc MAbs that were tested
in prior studies against pseudoviruses generated with the envelope
variants used here (Blish et al., 2008, 2009; Rainwater et al., 2007;
Wu et al., 2006). Of note, the envelopes under study exhibited a
range of sensitivities to these MAbs, which included two (2F5 and
4E10) that target adjacent conserved epitopes in the membrane prox-
imal external region (MPER) of gp41 (Muster et al., 1993; Zwick et al.,
2001) and one (IgG1 MAb b12), which targets a discontinuous epi-
tope overlapping the CD4 binding pocket (Burton et al., 1994).
When the pseudoviruses and chimeras generated in 293T cells were
compared using the three MAbs there was no signiﬁcant difference
in the distributions of IC50s between the two groups (Fig. 3A, b12:
p=0.3; Fig. 3B, 4E10: p=0.85; Fig. 3C, 2 F5: p=0.16). The IC50s of
the pseudoviruses were in good agreement with the published results
(Blish et al., 2008, 2009; Rainwater et al., 2007; Wu et al., 2006),
when available (data not shown).
While no signiﬁcant overall differences between IC50s of the
293T-derived pseudoviruses and 293T-derived chimeras were ob-
served with these three MAbs, it is interesting to note that individual
viral variants were not always functionally equivalent when pro-
duced either as a pseudovirus or a chimera. Speciﬁcally, the
QD435.A4 envelope was >10-fold more sensitive to neutralization
in the context of a pseudovirus compared to a chimera when tested
against the MAbs 4E10 and 2F5 (Figs. 3B and C, open diamond; Sup-
plemental Table 2), but was equally sensitive to b12 (Fig. 3A; Supple-
mental Table 2). Against 4E10 the chimera failed to reach 50%
neutralization, whereas the pseudovirus was neutralized 50% at
b2.5 μg/ml. Against 2F5, the pseudovirus was sensitive to neutraliza-
tion (IC50 of 3.8 μg/ml) while the chimera was neutralized b50% at
the highest concentration of antibody tested. In contrast, 293T-
derived BJ412.S3 chimera (Fig. 3B, ﬁlled circle; Supplemental Table
2) was approximately four-fold more sensitive the neutralization by
4E10 than the corresponding pseudovirus. These results demonstrate
that while pseudovirus and replication-competent chimera generated
in 293T cells are generally comparable, there are some virus-speciﬁc
differences, as was also observed by Louder et al. (2005).
To determine if the decreased sensitivity of PBMC-derived virus
observed for plasma antibodies was also observed when MAbs were
used, 293T-derived and PBMC-derived chimeras were compared.
The PBMC-derived chimera was more resistant to neutralizationthan the 293T-derived chimera for all three MAbs tested (Fig. 3; Sup-
plemental Table 2). While only 4E10 was found to require signiﬁcant-
ly higher MAb levels to achieve neutralization of PBMC virus (Fig. 3B;
p=0.008), in all cases the PBMC-derived virus was more resistant to
neutralization than analogous virus produced in 293T cells. In fact,
every PBMC-derived chimera variant failed to reach 50% neutraliza-
tion at the highest concentration of antibody tested when 4E10 and
2F5 were used (Figs. 3B and C). When b12 was used, four of the var-
iants that were neutralized when grown in 293T cells were no longer
neutralized when grown in PBMCs, and the other two viruses,
BS208.B1 chimera and QD435.A4 chimera, were more resistant
(Fig. 3A). A limitation of these ﬁndings was the relatively poor neu-
tralizing potency of b12, 4E10, and 2F5 against the viruses employed.
Hence, statistical signiﬁcance was unachievable, despite a trend in in-
creased neutralization resistance, with b12 and 2F5 because more
than 50% of the chimeras were not neutralized, even when grown in
293T cells (Figs. 3A and C).
In general, virus derived after PBMC passage was also not neutral-
ized by a combination of the three MAbs (tested at a combined con-
centration of 50 μg/ml total MAb). The exception was QD435.A4,
which exhibited moderate sensitivity to the combined MAbs (IC50
19 μg/ml; data not shown). These ﬁndings support the previous
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to neutralization by monoclonal antibodies compared to virus derived
by transient transfection of 293T cells (Louder et al., 2005; Mann et
al., 2009).The effect of producer cell on neutralization by highly potent MAbs,
VRC01 and PG9
TwoMAbs, VRC01 and PG9, that exhibit previously unprecedented
neutralization breadth and potency have recently been described
(Walker et al., 2009; Wu et al., 2010). VRC01 is a CD4 binding site di-
rected antibody (Wu et al., 2010). PG9 is directed against the variable
loops of gp120, and its target is thought to be a quaternary structure
formed by the envelope trimer that includes glycans (Walker et al.,
2009). Given the notable differences in neutralization sensitivity be-
tween 293T-derived versus PBMC-derived virus with plasma and
the other MAbs, we examined the neutralization potential of VRC01
and PG9 against viruses generated in these two cell types. In the
case of VRC01, PBMC-derived chimeras were more resistant to neu-
tralization than 293T-derived chimeras (Fig. 4A; p=0.0078). Both
the median IC50 of the PBMC-derived chimera was approximately
6-fold greater than the 293T-derived chimera (Supplemental Table
3) and each isolate was more neutralization resistant when generated
in PBMCs as compared to 293T cells. These ﬁndings are consistent
with the observations made using the other less broadly neutralizing
antibodies.
Surprisingly, there was no difference in the neutralization sensi-
tivity of PBMC- versus 293T-derived viruses using the MAb PG9. The
median IC50s of 293T-derived chimeras and PBMC-derived chimeras
were comparable when PG9 was used (Fig. 4B; p=0.95). For seven
virus pairs, there was a less than three-fold difference in neutraliza-
tion sensitivity between viruses obtained from the two growth condi-
tions. However, one of the chimeric viruses, QB099.B1, was
approximately 77-fold more sensitive to neutralization when grownFig. 4. Neutralization potency of VRC01 and PG9 against 293T-derived versus PBMC-
derived replication-competent chimeras. The layout for this ﬁgure is similar to that de-
scribed in the legend to Fig. 2. (A) Viruses tested against PG9 (Walker et al., 2009).
(B) Viruses tested against VRC01 (Wu et al., 2010). Each symbol represents the mean
IC50 of the virus indicated to the right, calculated from aminimum of two experiments,
performed in triplicate.in PBMCs compared to 293T cells (Supplemental Table 3). In contrast,
Q23-17 env chimera displayed neutralization characteristics more
comparable to what was observed with the other antibodies. The
293T-derived chimera displayed an IC50 of 0.011 μg/ml, whereas
the PBMC-derived chimera had an IC50 of 4.50 μg/ml, a more than
400-fold decrease in neutralization sensitivity for the PBMC-derived
virus (Supplemental Table 3). Thus, for the majority of MAbs tested
(b12, 4E10, 2F5, and VRC01), PBMC-derived chimeras displayed in-
creased neutralization resistance compared to 293T-derived chi-
meras, with only PG9 displaying comparable potency between the
two growth conditions overall.
Envelope levels in PBMC- versus 293T-derived viruses
We performed Western blot analyses to determine if differences
in neutralization sensitivity between viruses derived from 293T ver-
sus PBMC were related to differences in Envelope levels. The results
of these experiments are summarized in Fig. 5. Overall, there were
no differences in the amount of Envelope cleavage between viruses
derived from the two cell populations (Fig. 5A). To estimate the rela-
tive Envelope density of the different viruses, Envelope levels were
calculated in relation to p24 levels. There was no statistically signiﬁ-
cant difference in the ratio of total Envelope (gp120 plus gp160)/
p24 between viruses generated in 293T versus PBMC viruses
(p=0.11; Fig. 5B). However, PBMC-derived viruses had a trend to-
wards signiﬁcantly higher gp120/p24 ratios compared to 293T-
derived viruses (p=0.079; Fig. 5C). The magnitude of this difference
was small, less than 2-fold overall. Interestingly, there were some vi-
ruses with a greater than 2-fold difference in gp120/p24 levels, such
as QA013 (3-fold greater expression on PBMC-derived virus) and
QB099 (3.6-fold lower expression on PBMC-derived virus). However,
these differences in gp120/p24 ratio were not reﬂected by consistent
differences in neutralization patterns. For example, for QA013, the
PBMC-derived virus was more resistant to VRC01 and PG9 than its
293T-derived counterpart, but displayed no differences (less than 2-
fold) in sensitivity to the polyclonal plasma. In comparison, with
QB099, the PBMC-derived virus showed similar sensitivity to VRC01
(less than 2-fold difference in IC50), increased sensitivity to PG9 com-
pared to 293T-derived virus, but four-fold decreased sensitivity to the
polyclonal plasma pool. Overall, there was no correlation between
Envelope levels, as measured by either total Env/p24 or gp120/p24,
and neutralization sensitivity, as deﬁned by IC50 values, to either
the plasma pool or the MAbs PG9 and VRC01 (Supplemental Fig. 1).
Discussion
The ﬁndings of this study demonstrate that most viruses generat-
ed in lymphocyte cultures are more resistant to antibody neutraliza-
tion than virus generated by transfection of 293T cells; this is
consistent with previous studies utilizing clade B viruses (Louder et
al., 2005; Mann et al., 2009). Thus, the current assays that rely on
293T-derived virus likely overestimate the true potency of the anti-
body under study. This can be seen as a positive feature of such as-
says, as it allows better detection of neutralizing antibody responses
with less antibody. However, when considering the true potency of
the antibody – that is the amount needed to neutralize virus pro-
duced by the typical target cells for HIV-1 in vivo – it is important
to keep in mind that viruses in vivo may be signiﬁcantly less sensitive
to neutralization than the test virus. Unfortunately, it is not possible
to directly calculate such a difference for any given virus or antibody,
because there is considerable variation in the producer cell effect
depending on the antibody as well as the speciﬁc virus. Here we
found there is a signiﬁcant producer cell effect with some broadly
neutralizing MAbs such as VRC01, b12, 2F5, and 4E10, as well as
pooled plasma from HIV-1 infected individuals, but this was not
Fig. 5. Quantiﬁcation of Envelope processing and envelope incorporation of 293T-
derived and PBMC-derived replication competent chimeras. The source of the virus is
shown on the x-axis: 293T-Chm denotes virus obtained by transfecting 293T cells
with a chimeric provirus; PBMC-Chm denotes virus obtained by infecting PBMCs
with 293T-derived chimeric virus. The envelope of the various virus types is indicated
to the right with the corresponding symbol. Quantitative Western blotting was per-
formed to determine the amount of gp120, gp160, and p24 (see Materials and
methods). (A) The % cleavage was calculated as integrated intensity (i.i.) of gp120/
(i.i. gp120+i.i. gp160). (B) The total Env/p24 was calculated as (i.i. gp120+i.i.
gp160)/ i.i. p24. (C) Amount of gp120/p24 was calculated as the integrated i.i. gp120/
i.i. p24. The P-value, shown above each ﬁgure, was calculated by Wilcoxon signed-
rank test. Each symbol represents average data from two experiments.
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that the median difference in IC50 between the 293T-derived and
PBMC-derived viruses was less than a ﬁve-fold difference, the inﬂated
Ab potency determined using 293T-derived viruses is likely to be only
several-fold in most cases. Interestingly, some viruses from lympho-
cytes were more resistant to one antibody but not another, while
others were more resistant to all antibodies, suggesting there is likely
no one feature of lymphocyte-derived viruses that explains their neu-
tralization resistance.
Isogenic pseudoviruses and replication-competent chimeras gen-
erated in the same 293T producer cell were generally equivalent in
neutralization sensitivity to the MAbs tested. This ﬁnding is consis-
tent with a previous study using clade B viruses from chronic infec-
tion (Louder et al., 2005). Here, we observed that the chimeras
generated in 293T cells were most resistant to antibodies in plasma
for HIV-1-infected individuals than the corresponding pseudovirus,
although the magnitude of the difference is small (~2-fold). For
both MAbs and plasma, isolate speciﬁc variation was observed.There are multiple non-exclusive explanations for the decreased
neutralization sensitivity of the PMBC-derived compared to 293T-
derived chimeras. Several studies have demonstrated that changes
in the glycosylation of envelope can alter neutralization sensitivity
(Duenas-Decamp et al., 2008; Utachee et al., 2010). A study compar-
ing the effect of PBMCs versus macrophages as producer cell on neu-
tralization sensitivity found macrophage-derived viruses were more
resistant to neutralization than PBMC-derived viruses, and this was
correlated with different glycosylation between the two cell types
(Willey et al., 1996). Furthermore, a study examining the effect of
producer cell type on amount and type of glycans found signiﬁcant
differences in gp120 glycosylation when produced in different cell
lines, including 293T cells and Jurkat cells (Raska et al., 2010). These
differences in glycosylation were shown to alter binding of IgG puri-
ﬁed from HIV-1 infected individuals to gp120. If differences in glycan
structure are important in driving differences between neutralization
sensitivity of viruses made in 293T cells and PBMCs, then the results
with PG9 are somewhat surprising. Glycans on Env have been
shown to be critical for neutralization of virus by PG9 (Walker et al.,
2009), and therefore changes in virus growth that alter the properties
of envelope glycans would have been predicted to have the greatest
impact on PG9 recognition, as observed for another glycan-
dependent MAb, 2G12 (Mann et al., 2009). We did observe two virus-
es where the producer cell had a dramatic affect on PG9 recognition,
in one case, the PBMC-derived virus was more neutralization sensi-
tive and in the other, the opposite was true. These variants may
hold clues to the features of viruses from different sources that
drive neutralizing antibody recognition.
We examined whether the total amount of envelope, or the form
of envelope present on the virion correlated with neutralization sen-
sitivity. There was no overall correlation between envelope levels and
neutralization sensitivity among the viruses tested, suggesting that
the inherent antigenic properties of individual viral variants, not en-
velope density on the virion, is the major determinant of neutraliza-
tion sensitivity, as observed in a prior study (Blish et al., 2008).
While the neutralization proﬁle may be largely deﬁned by nature
of the viral variant itself, for an individual viral variant, differences
in envelope density due to producer cell type could nonetheless con-
tribute to the observed differences in neutralization susceptibility of a
PBMC-derived virus compared to its 293T-derived counterpart. We
found that the ratio of gp120 to p24 was higher for PBMC-derived vi-
ruses than for 293T viruses, suggesting a higher gp120 density for vi-
ruses generated in PBMCs. This is consistent with a prior study of
three subtype B viruses which showed relatively few envelope spikes
on 293T-derived chimeras (between one and three) compared to
PBMC-derived virus [(an estimated 12 and 19 spikes;(Louder et al.,
2005)]. The magnitude of the differences observed here for viruses
from diverse subtypes was much more modest, overall less than
two-fold. Moreover, virus pairs that showed the greatest differences
in gp120/p24 levels based on producer cell type did not show a corre-
sponding consistent change in neutralization sensitivity. Indeed,
there are studies that suggest a relationship between increased enve-
lope levels and increased neutralization resistance (Blay et al., 2007)
and others that do not (Provine et al., 2009). Thus, it is possible that
Envelope density may contribute to the decreased neutralization sen-
sitivity of the PBMC-derived viruses for some viral variants, but this is
not generally the case. The fact that not all viruses or virus/antibody
combinations are affected by producer cell also suggests that the
basis for these differences in neutralization sensitivity due to produc-
er cell may be complex.
As part of this study, we have developed nine novel replication-
competent chimeras comprising envelope variants from the most
common circulating HIV-1 subtypes, A, C, and D. Six are from early
in infection in adults who acquired HIV-1 through sexual contact
and three are from recently infected infants. These proviral clones
produce high titer virus when transfected into 293T cells, and nine
31N.M. Provine et al. / Virology 427 (2012) 25–33of the 12 chimeras tested established a high level infection of human
PBMCs. Thus, these chimeric proviruses should be useful for examin-
ing the potential of interventions such as vaccines and microbicides
to inhibit globally relevant viruses produced in primary cells. Since
these viruses are replication-competent, they can also be employed
in a range of cell types, including organ cultures and other models
used to study early events in HIV-1 infection.
In conclusion, in this study of a novel panel of globally relevant
HIV-1 envelope variants, we found that producer cell type has a dra-
matic effect on neutralization sensitivity. Pseudoviruses, which are
employed in the most commonly used HIV-1 neutralization assays,
are the most sensitive form of the virus, and thus may overestimate
the potency of most HIV-1 antibodies. Lymphocyte-derived viruses
were less sensitive to neutralization by the MAbs b12, 4E10, 2F5,
and VRC01, as well as polyclonal plasma antibodies. However, it is no-
table that the producer cell did not affect neutralization by PG9 in
most cases. Thus, these ﬁndings suggest complex determinants of
neutralization sensitivity that are signiﬁcantly affected by the cellular
origin of the virus.
Materials and methods
HIV-1 plasmids
The HIV-1 envelopes used in this study have all been previously
described. Three, BJ412.W6M.ENV.S3, BJ613.W6M.ENV.E1, and
BS208.W6M.ENV.B1 are from recently infected Kenyan infants and
two, MG505.W0M.ENV.C2 and MS208.W6B.ENV.A3 are from chroni-
cally infected mothers in the same study (Rainwater et al., 2007;
Wu et al., 2006). Seven are envelope clones derived from recently
infected Kenyan women, QA013.70I.ENV.M12, QB099.391M.ENV.B1,
QC406.70M.ENV.F3, QD435.100M.ENV.A4, Q168.b23, Q461.e2, and
Q23-17 env (Blish et al., 2009; Long et al., 2002). The envelope
clone names are abbreviated in the paper to include only the subject
ID and the clone number; for example, QA013.70I.ENV.M12 is desig-
nated QA013.M12. Q23Δenv was generated from a clade A HIV-1 pro-
viral genome (Q23-17) (Poss and Overbaugh, 1999) by engineering
an out-of-frame deletion in env (Long et al., 2002). Full-length chi-
meras were generated from the parental Q23-17 infectious proviral
clone (Genbank ID: AF004885), as previously described (Provine et
al., 2009). Brieﬂy, a derivative of Q23-17 (Q23XhoΔXho) that was
engineered to encode a XhoI site in nef (A to G transition at base
8358 resulting in an amino acid change of glutamine to glutamic
acid) was digested with SmaI and XhoI, gel puriﬁed and ligated to a
SmaI/XhoI digested fragment encoding the envelope genes of interest
(the envelope clones under study were ampliﬁed with primers that
contained the desired SmaI and XhoI sites — see references above
for source of virus and primers employed) The resulting chimeric pro-
virus was veriﬁed by restriction site digestion and sequence analysis
of the whole envelope gene and ﬂanking Q23 genomic sequence.
Virus preparation in 293T cells
Viruses were generated by transfection of 293T cells using FuGENE
6 Transfection Reagent (Roche, Mannheim, Germany). In all in-
stances, 293T cells were plated at 2×106 cells in a T-75 ﬂask. After
1 day, 4 μg of total plasmid DNA was incubated with 388 μl DMEM
and 12 μl of FuGENE, incubated at RT for 15 min, and added dropwise
to the cells. The pseudoviruses were generated by cotransfection of
the Q23Δenv plasmid and respective env plasmid at a 1:1 M ratio;
for the replication-competent viruses, 4 μg of plasmid was trans-
fected. After 48 h, virus was harvested, cellular debris was removed
by ﬁltration through a 0.22 μm ﬁlter (Steriﬂip, Millipore Corporation,
Billerica, MA), and the viral supernatant was stored at−80 °C for fu-
ture use.Virus preparation in peripheral blood mononuclear cells
PBMCs from HIV-1 negative donors were isolated as previously
described (Mascola et al., 2002) and resuspended in complete RPMI
(RPMI+10% FBS (fetal bovine serum) +1% L-Glutamine+1% PSF
(Penicillin, Streptomycin, and Fungizone) +10 U/ml interleukin 2
(IL-2) +10 μg/ml phytohemagglutinin (PHA). After ~48 h at 37 °C,
cells were pelleted, washed in PBS, and resuspended in complete
RPMI plus IL-2 without PHA at a concentration of 2×106 cells/ml
and returned to 37 °C. After a further 48 h incubation, 2×107
PBMCs at 6.7×106 cells/ml were infected with the virus derived
from transfected 293T cells, at a multiplicity of infection of 0.01.
After one hour incubation at 37 °C, cells were gently pelleted by cen-
trifugation at 400×g for 5 min at room temperature, supernatant was
removed and the cells were returned to a concentration of
2×106cells/ml. Every 72 h, cells were pelleted, supernatant was re-
moved, aliquoted and frozen at−80 °C. The PBMCs were subsequent-
ly resuspended at 2×106 cells/ml for additional culture over a course
of 15 days.
Determination of viral infectivity
The infectious titer of viruses generated by transfection of 293T
cells or infection of PBMCs was determined by infecting TZM-bl
cells (Platt et al., 1998; Wei et al., 2003) and enumerating blue foci
as described (Vodicka et al., 1997). Brieﬂy, 100 μl of serially diluted
virus supernatant was added to 2×104 TZM-bl cells in 500 μl of com-
plete DMEM media (DMEM +10% FBS, 1% L-Glutamine, and 1% PSF)
+0.6 μg of DEAE-Dextran, and incubated at 37 °C. After 48 h the su-
pernatant was removed and 500 μl of a 2.7% formaldehyde and 0.8%
gluteraldehyde solution in PBS was added to ﬁx the cells. After a max-
imum of 10 min the ﬁx solution was removed and the cells were
washed three times in PBS. The PBS was subsequently removed and
200 μl of the staining solution (0.004 M Potassium Ferrocyanide,
0.004 M Potassium Ferricyanide, 0.002 M MgCl2, and 0.4 mg/ml X-
gal) was added. The cells were stained for 50 min at 37 °C after
which time the staining solution was removed, cells were washed
in PBS, and wells that contained between 30 and 300 blue foci were
counted. The number of infectious particles per ml was then calculat-
ed based on the dilution. Each experiment was performed in dupli-
cate, at least twice using two separate transfections.
Tier designation
The Tier designation for these envelope variants was estimated
using the data and methods of Seaman et al. (2010). It was not possi-
ble to directly compare the Tier cutoffs deﬁned by Seaman with the
IC50s of viruses used here because different plasma were used to de-
ﬁne the IC50 values. However, because some of the envelope variants
from our studies were analyzed in the prior study and determined to
be Tier 2 viruses (Seaman et al., 2010), we were able to compare the
relative sensitivity of these known Tier 2 variants versus the ones
studied here using IC50s that were determined using the same pooled
plasma (Blish et al., 2007a, 2009). This comparison was used to esti-
mate the Tier designation.
Neutralization assay
Neutralization assays were performed using TZM-bl cell targets as
previously described (Blay et al., 2007;Wu et al., 2006). Themonoclo-
nal antibodies 2F5 and 4E10 (acquired from the AIDS Research and
Reference Reagent Program, National Institutes of Health) and IgG1
b12 (kindly provided by Dennis Burton) were used at a maximum
concentration of 20, 25, and 25 μg/ml, respectively. The monoclonal
antibodies PG9 (kindly provided by Dennis Burton and the IAVI
NAC) and VRC01 (kindly provided by John Mascola and the VRC
32 N.M. Provine et al. / Virology 427 (2012) 25–33team) were used at a maximum concentration of 5 μg/ml. An HIV pos-
itive plasma pool, generated from 31 HIV-1-infected women from
Kenya who had CD4 counts >500 cells/ml, was used at a starting di-
lution of 1:27. Each antibody or plasma was serially diluted two-
fold and incubated with 500 infectious particles based on the titer
in TZM-bl cells as described above. For viruses where an IC50 could
not be determined for PG9 and VRC01, the MAbs were diluted ﬁve-
fold. The antibody and virus were incubated for 1 h, after which
time, 104 TZM-bl cells and 10 μg/ml DEAE-Dextran were added to
each well. After 48 h, luciferase activity was subsequently measured
by a Thermo Scientiﬁc luminometer (Waltham, MA) using the
Galacto-Lite Plus kit per the manufacturer's instructions (Applied Bio-
systems, Foster City, CA). At each dilution, percent neutralization was
calculated as [(value for virus only−value for cell only)−(value for
antibody−value for cell only)] /(value for virus only−value for cell
only). The 50% inhibitory concentration was calculated by interpola-
tion of the linear regression of the neutralization curves converted
to a logarithmic scale, performed in Microsoft Excel (Microsoft, Red-
mond, WA). In cases where the 50% inhibitory concentration was
greater or less than the concentrations tested the value was reported
as the maximum or minimum concentration/dilution, respectively.
All experiments using monoclonal antibodies were performed twice,
in triplicate, using virus generated by two independent transfections,
and all results that did not agree within 2.5-fold were repeated two
further times. The average IC50 was determined using all replicates.
All neutralization experiments using the HIV-1 positive plasma pool
were performed three times, in triplicate, using virus from at least
two transfections.
Western blots
Puriﬁed pseudoviral preparations were prepared for Western
blotting as previously described (Blish et al., 2007b; Lovelace et al.,
2011). Brieﬂy, pseudoviral supernatants were pelleted by microcen-
trifugation and resuspended in lysis buffer [1% Triton X-100
(Sigma)/PBS]. Samples were resolved on a 4–12% gradient Bis–Tris
polyacrylamide gel (Invitrogen), followed by electrotransfer to a ni-
trocellulose membrane. A rabbit polyclonal antisera to HIV-1 Env
(Doria-Rose et al., 2005) and mouse anti-p24 (cat. no. 4121; NIH
AIDS Research and Reference Reagent Program) were used as a pri-
mary antibodies, with IRDye700DX-conjugated goat-anti-rabbit IgG
and IRDye800DX-conjugated goat-anti-mouse IgG as secondary anti-
bodies (Rockland Immunochemicals), respectively. Western blotting
and protein quantiﬁcation were performed using the Odyssey infra-
red imagining system (LI-COR Biosciences). Percent cleavage was cal-
culated as the signal due to gp120 over the signal due to total
envelope protein (gp120 plus gp160). Amount of total Env/p24 was
calculated as (gp160 plus gp120)/p24 and gp120/p24 was calculated
by quantiﬁcation of the gp120 and p24 bands. Western blot analysis
was performed twice and the average values for the two experiments
are presented in Fig. 5.
Supplementary materials related to this article can be found on-
line at doi: 10.1016/j.virol.2012.02.001.
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